Cargando…
Mining Natural Products for Macrocycles to Drug Difficult Targets
[Image: see text] Lead generation for difficult-to-drug targets that have large, featureless, and highly lipophilic or highly polar and/or flexible binding sites is highly challenging. Here, we describe how cores of macrocyclic natural products can serve as a high-quality in silico screening library...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872424/ https://www.ncbi.nlm.nih.gov/pubmed/33337880 http://dx.doi.org/10.1021/acs.jmedchem.0c01569 |
_version_ | 1783649182703157248 |
---|---|
author | Begnini, Fabio Poongavanam, Vasanthanathan Over, Björn Castaldo, Marie Geschwindner, Stefan Johansson, Patrik Tyagi, Mohit Tyrchan, Christian Wissler, Lisa Sjö, Peter Schiesser, Stefan Kihlberg, Jan |
author_facet | Begnini, Fabio Poongavanam, Vasanthanathan Over, Björn Castaldo, Marie Geschwindner, Stefan Johansson, Patrik Tyagi, Mohit Tyrchan, Christian Wissler, Lisa Sjö, Peter Schiesser, Stefan Kihlberg, Jan |
author_sort | Begnini, Fabio |
collection | PubMed |
description | [Image: see text] Lead generation for difficult-to-drug targets that have large, featureless, and highly lipophilic or highly polar and/or flexible binding sites is highly challenging. Here, we describe how cores of macrocyclic natural products can serve as a high-quality in silico screening library that provides leads for difficult-to-drug targets. Two iterative rounds of docking of a carefully selected set of natural-product-derived cores led to the discovery of an uncharged macrocyclic inhibitor of the Keap1-Nrf2 protein–protein interaction, a particularly challenging target due to its highly polar binding site. The inhibitor displays cellular efficacy and is well-positioned for further optimization based on the structure of its complex with Keap1 and synthetic access. We believe that our work will spur interest in using macrocyclic cores for in silico-based lead generation and also inspire the design of future macrocycle screening collections. |
format | Online Article Text |
id | pubmed-7872424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-78724242021-02-10 Mining Natural Products for Macrocycles to Drug Difficult Targets Begnini, Fabio Poongavanam, Vasanthanathan Over, Björn Castaldo, Marie Geschwindner, Stefan Johansson, Patrik Tyagi, Mohit Tyrchan, Christian Wissler, Lisa Sjö, Peter Schiesser, Stefan Kihlberg, Jan J Med Chem [Image: see text] Lead generation for difficult-to-drug targets that have large, featureless, and highly lipophilic or highly polar and/or flexible binding sites is highly challenging. Here, we describe how cores of macrocyclic natural products can serve as a high-quality in silico screening library that provides leads for difficult-to-drug targets. Two iterative rounds of docking of a carefully selected set of natural-product-derived cores led to the discovery of an uncharged macrocyclic inhibitor of the Keap1-Nrf2 protein–protein interaction, a particularly challenging target due to its highly polar binding site. The inhibitor displays cellular efficacy and is well-positioned for further optimization based on the structure of its complex with Keap1 and synthetic access. We believe that our work will spur interest in using macrocyclic cores for in silico-based lead generation and also inspire the design of future macrocycle screening collections. American Chemical Society 2020-12-18 2021-01-28 /pmc/articles/PMC7872424/ /pubmed/33337880 http://dx.doi.org/10.1021/acs.jmedchem.0c01569 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. |
spellingShingle | Begnini, Fabio Poongavanam, Vasanthanathan Over, Björn Castaldo, Marie Geschwindner, Stefan Johansson, Patrik Tyagi, Mohit Tyrchan, Christian Wissler, Lisa Sjö, Peter Schiesser, Stefan Kihlberg, Jan Mining Natural Products for Macrocycles to Drug Difficult Targets |
title | Mining Natural
Products for Macrocycles to
Drug Difficult Targets |
title_full | Mining Natural
Products for Macrocycles to
Drug Difficult Targets |
title_fullStr | Mining Natural
Products for Macrocycles to
Drug Difficult Targets |
title_full_unstemmed | Mining Natural
Products for Macrocycles to
Drug Difficult Targets |
title_short | Mining Natural
Products for Macrocycles to
Drug Difficult Targets |
title_sort | mining natural
products for macrocycles to
drug difficult targets |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872424/ https://www.ncbi.nlm.nih.gov/pubmed/33337880 http://dx.doi.org/10.1021/acs.jmedchem.0c01569 |
work_keys_str_mv | AT begninifabio miningnaturalproductsformacrocyclestodrugdifficulttargets AT poongavanamvasanthanathan miningnaturalproductsformacrocyclestodrugdifficulttargets AT overbjorn miningnaturalproductsformacrocyclestodrugdifficulttargets AT castaldomarie miningnaturalproductsformacrocyclestodrugdifficulttargets AT geschwindnerstefan miningnaturalproductsformacrocyclestodrugdifficulttargets AT johanssonpatrik miningnaturalproductsformacrocyclestodrugdifficulttargets AT tyagimohit miningnaturalproductsformacrocyclestodrugdifficulttargets AT tyrchanchristian miningnaturalproductsformacrocyclestodrugdifficulttargets AT wisslerlisa miningnaturalproductsformacrocyclestodrugdifficulttargets AT sjopeter miningnaturalproductsformacrocyclestodrugdifficulttargets AT schiesserstefan miningnaturalproductsformacrocyclestodrugdifficulttargets AT kihlbergjan miningnaturalproductsformacrocyclestodrugdifficulttargets |